Atara Biotherapeutics Inc (NASDAQ:ATRA) CEO Isaac E. Ciechanover sold 7,800 shares of the firm’s stock in a transaction on Tuesday, May 14th. The shares were sold at an average price of $24.61, for a total value of $191,958.00. Following the completion of the transaction, the chief executive officer now owns 332,243 shares in the company, valued at approximately $8,176,500.23. The sale was disclosed in a document filed with the SEC, which is accessible through this link.
Shares of NASDAQ:ATRA traded down $0.73 during midday trading on Thursday, reaching $24.12. 21,716 shares of the company’s stock were exchanged, compared to its average volume of 550,702. The company has a current ratio of 9.96, a quick ratio of 9.96 and a debt-to-equity ratio of 0.05. The company has a market capitalization of $1.12 billion, a price-to-earnings ratio of -4.58 and a beta of 2.11. Atara Biotherapeutics Inc has a fifty-two week low of $23.58 and a fifty-two week high of $54.45.
Atara Biotherapeutics (NASDAQ:ATRA) last issued its quarterly earnings data on Thursday, May 9th. The biotechnology company reported ($1.44) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($1.48) by $0.04. As a group, equities research analysts predict that Atara Biotherapeutics Inc will post -5.93 earnings per share for the current fiscal year.
A number of research analysts have weighed in on ATRA shares. Mizuho started coverage on Atara Biotherapeutics in a report on Tuesday, January 22nd. They issued a “buy” rating and a $62.00 price objective on the stock. BidaskClub upgraded Atara Biotherapeutics from a “hold” rating to a “buy” rating in a report on Thursday, February 7th. ValuEngine lowered Atara Biotherapeutics from a “strong-buy” rating to a “buy” rating in a report on Tuesday, February 12th. Cowen reiterated a “buy” rating on shares of Atara Biotherapeutics in a report on Tuesday, February 26th. Finally, Zacks Investment Research lowered Atara Biotherapeutics from a “hold” rating to a “sell” rating in a report on Monday, March 4th. Two analysts have rated the stock with a sell rating, one has assigned a hold rating and five have issued a buy rating to the company. The stock currently has an average rating of “Hold” and an average price target of $43.33.
Several large investors have recently modified their holdings of the stock. FMR LLC increased its position in shares of Atara Biotherapeutics by 21.7% during the 1st quarter. FMR LLC now owns 6,417,956 shares of the biotechnology company’s stock worth $255,114,000 after purchasing an additional 1,143,787 shares during the last quarter. Maverick Capital Ltd. acquired a new position in Atara Biotherapeutics in the 1st quarter valued at about $34,613,000. Man Group plc acquired a new position in Atara Biotherapeutics in the 1st quarter valued at about $1,128,000. Coastal Investment Advisors Inc. acquired a new position in Atara Biotherapeutics in the 1st quarter valued at about $142,000. Finally, Marshall Wace LLP acquired a new position in Atara Biotherapeutics in the 1st quarter valued at about $284,000.
Atara Biotherapeutics Company Profile
Atara Biotherapeutics, Inc, an off-the-shelf T-cell immunotherapy company, develops treatments for patients with cancer, autoimmune, and viral diseases in the United States. It is developing tabelecleucel, a T-cell immunotherapy that is Phase III clinical trials for the treatment of rituximab-refractory epstein-barr virus (EBV) associated post-transplant lymphoproliferative disorder, as well as other EBV associated hematologic and solid tumors, including nasopharyngeal carcinoma.
Recommended Story: Trade Deficit
Receive News & Ratings for Atara Biotherapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Atara Biotherapeutics and related companies with MarketBeat.com's FREE daily email newsletter.